Equity Overview
Price & Market Data
Price: $16.05
Daily Change: +$0.26 / 1.62%
Daily Range: $15.90 - $16.10
Market Cap: $2,099,611,648
Daily Volume: 3,600
Performance Metrics
1 Week: 12.95%
1 Month: 10.27%
3 Months: 3.20%
6 Months: 39.12%
1 Year: 108.0%
YTD: -1.00%
Company Details
Employees: 128
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.